Christopher Bergman
Optometrist · Omaha, NENPI 1538175567
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 129 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 22 manufacturers reported payments, led by AbbVie at 39.2% of the total. 2025 is the largest year on record at $908, 2.7 times the $337 reported in 2019. Among optometrist clinicians in NE with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 129 payments — averaging $23.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Bausch & Lomb Americas Inc.$393
- Amgen$334
- Bausch & Lomb, A Division Of Bausch Health US, LLC$183
- Aerie Pharmaceuticals, Inc.$152
- Astellas Pharma US Inc$151
- plus $631 from 16 others
What the payments were for
- Food & beverage$3,034100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 68 | $1,191 |
| Bausch & Lomb Americas Inc. | 15 | $393 |
| Amgen(2 entities) | 10 | $334 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $183 |
| Aerie Pharmaceuticals, Inc. | 3 | $152 |
| Astellas Pharma US Inc | 2 | $151 |
| Tarsus Pharmaceuticals, Inc. | 4 | $117 |
| Biotissue Holdings Inc. | 1 | $93 |
| Novartis | 6 | $87 |
| Rxsight Inc | 2 | $63 |
| Alcon | 2 | $45 |
| Zimmer Biomet | 1 | $41 |
| Sun Pharmaceutical Industries Inc. | 2 | $36 |
| Harrow Eye, LLC | 1 | $24 |
| Thea Pharma Inc. | 1 | $22 |
| Dompe US, Inc. | 1 | $20 |
| The Cameron-ehlen Group, Inc. | 1 | $18 |
| Sight Sciences, Inc. | 1 | $16 |
| Coherus Oncology, Inc. | 1 | $14 |
| Oyster Point Pharma, Inc. | 1 | $14 |
| Johnson & Johnson Surgical Vision, Inc. | 1 | $12 |
| Shire North American Group Inc | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,034 in reported general payments places this provider in the 90th percentile of 383 optometrist providers in Nebraska.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| LumiganBimatoprost | 75 | $31,605 |
| RestasisCyclosporine | 16 | $11,051 |
| Travoprost | 70 | $9,430 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 13 | $5,755 |
| Brimonidine Tartrate | 226 | $5,061 |
| Latanoprost | 612 | $4,686 |
| Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol | 21 | $3,880 |
| Timolol Maleate | 255 | $2,777 |
| Dorzolamide Hcl | 111 | $1,496 |
| Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat | 69 | $1,173 |
| Prednisolone Acetate | 26 | $1,139 |
| MoxifloxacinMoxifloxacin Hcl | 12 | $434 |
| Doxycycline Hyclate | 13 | $240 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieLumigan, Restasis | $1,191 | $42,65691 claims |
| AlconSimbrinza | $45 | $5,75513 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 383 optometrist providers in Nebraska.
Other optometrist in Omaha
- Christopher WolfeOmaha$154K
- Mark ToelleOmaha$10K
- John GoertzOmaha$8K
- Jordan ArensOmaha$7K
- Holly TernusOmaha$6K
- Marsha KubicaOmaha$6K
- Delaney KentOmaha$5K
- Adam WalterOmaha$5K
- Kelly RobertsonOmaha$5K
- Kristen WaltonOmaha$5K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.